CellGenix – which makes good manufacturing practice (GMP) grade raw materials for cell and gene therapies and tissue-engineered products – has completed the first stage of its facility expansion plan.
Now that the quality control and R&D laboratories and logistics and warehouse space expansion is completed, the firm will implement an automated filling and freeze-drying line into the existing GMP facility.
The second phase of expansion aims to increase finished product capacity for recombinant proteins tenfold and is due to be completed in spring 2019.
The German firm instigated the expansion in February last year, to help ‘stay on top’ of growing demand for GMP cell culture reagents as customers’ cell and gene therapies near late-stage clinical development and commercialisation.
“With this expansion we strengthen our position as a leading partner for all companies active in the manufacturing of cell and gene therapies. It enables us to meet increasing demands for high quality raw materials and, ultimately, help more patients,” said vice president of marketing and sales Frank Hecht in a statement.